ufpt-20251201

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 1, 2025

_______________________________

UFP TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

_______________________________


Delaware	001-12648	04-2314970
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

100 Hale Street

Newburyport, Massachusetts - USA 01950-3504

(Address of Principal Executive Offices) (Zip Code)

(978) 352-2200

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	UFPT	The NASDAQ Stock Market L.L.C.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02             Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Chief Executive Officer

On December 1, 2025, R. Jeffrey Bailly, Chief Executive Officer of UFP Technologies, Inc., a Delaware corporation (the “Company”), announced his retirement from his position as Chief Executive Officer of the Company, effective as of the completion of the Company’s Annual Meeting of Stockholders currently scheduled for June 4, 2026 (the “Effective Date”). Mr. Bailly’s retirement was not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, including accounting principles and practices. Mr. Bailly intends to remain on the Board of Directors of the Company (the “Board”).

Appointment of Chief Executive Officer

Subject to Mitchell C. Rock’s execution and delivery of an Employment Offer Letter, in form and substance satisfactory to the Company, Mr. Rock will serve as the Chief Executive Officer of the Company, effective as of the Effective Date.

Mr. Rock, age 58, initially joined the Company in 1991 and served as Director, Sales and Marketing of what was the Company’s Moulded Fibre division. From May 1999 through October 2000, Mr. Rock left the Company to serve as Vice President, Sales and Business Development of Esprocket, an internet start-up company. Mr. Rock rejoined the Company in April 2001 as Vice President, Sales and Marketing of the Moulded Fibre division and served as the Company’s Vice President of Sales and Marketing from May 2002 to June 2014. From June 2014 to June 2021, Mr. Rock served as the Company’s Senior Vice President of Sales and Marketing, and from January 1, 2020 to June 2021, Mr. Rock also served as General Manager, Medical. From June 2021, Mr. Rock served as President, UFP MedTech. Since February 2024, Mr. Rock has served as President of the Company. Since 2016, Mr. Rock has also served on the board of directors of Outlook Amusements, Inc., an entertainment company specializing in advice-based products and services.

Other than the Employment Offer Letter, there are no arrangements or understandings between Mr. Rock and any other person pursuant to which Mr. Rock will be promoted to Chief Executive Officer of the Company. There are no family relationships between Mr. Rock and any director or executive officer of the Company, and he has no indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. For more information about Mr. Rock, please see the Company’s definitive proxy statement on DEF 14A, filed with the U.S. Securities and Exchange Commission on April 30, 2025.

Appointment of Executive Chairman of the Board

Additionally, on December 1, 2025, the Board appointed Mr. Bailly as Executive Chairman of the Board, effective as of the Effective Date. For more information about Mr. Bailly, please see the Company’s definitive proxy statement on DEF 14A, filed with the U.S. Securities and Exchange Commission on April 30, 2025.

Item 7.01             Regulation FD Disclosure.

On December 1, 2025, the Company issued a press release announcing the retirement of Mr. Bailly and the appointment of Mr. Rock as its Chief Executive Officer, a copy of which is furnished with this Current Report on Form 8-K as Exhibit 99.1.

Limitation on Incorporation by Reference. The information furnished in this Item 7.01, including the press release attached hereto as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the press release attached as an exhibit hereto, the press release contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


Exhibit Number						Description

99.1						Press Release dated D ecember 1 , 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	UFP Technologies, Inc.


Date: December 1, 2025	By:	/s/ Ronald J. Lataille
		Ronald J. Lataille
		Chief Financial Officer and Senior Vice President

UFP Technologies, Inc. www.ufpt.com

100 Hale Street Contact: Ron Lataille

Newburyport, MA 01950 USA 978-234-0926, [email protected]

FOR IMMEDIATE RELEASE

UFP Technologies Announces CEO Succession Plan

Newburyport, Mass., December 2, 2025. UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that R. Jeffrey Bailly will retire as CEO at the Company’s next annual meeting on June 4, 2026. At that time, Mitchell Rock, President of the Company, will assume the CEO position and join the Company’s Board. To facilitate a smooth transition, Mr. Bailly will serve as Executive Chairman of the Board for the following year.

“Serving as CEO for 31 years, Jeff has been an extremely effective leader who, together with his team, transitioned the company to a leading global contract development and manufacturing organization focused on medical markets, with locations in five countries,” said Dan Croteau, Lead Director of the Board. “During Jeff’s tenure, the Company’s revenue grew approximately 20-fold, and profitability and market capitalization grew more than 150-fold. We thank Jeff for his significant contributions, wish him all the best in his retirement, and look forward to his continued impact as Executive Chairman.”

“It has been my honor to lead the exceptional, innovative, and customer-focused team at UFP Technologies, whose dedication, hard work, and can-do attitude have made it the success it is today,” said Bailly. “I am extremely proud of this team of nearly 5,000 associates and all they have done, and continue to do, to make our customers successful. I am very grateful to all of them and to our Board of Directors. I am also very excited about the future of the company under Mitch Rock’s leadership. He has been a strategic partner for 25 years and is a very capable leader who is well-respected throughout our industry. With his deep understanding of the markets we serve, his strong relationships with our key customers and vendor partners, and the trust and respect of his co-workers, Mitch is the natural choice to be UFP’s next CEO.”

“I’m honored by the Board’s confidence and grateful for Jeff’s leadership and mentorship over many years,” said Mitch Rock, President. “As he transitions to Executive Chairman, I look forward to continuing our close partnership and building on our strong foundation. UFP Technologies has highly talented people, trusted customer relationships, and many exciting market opportunities. I’m committed to continuing to execute our proven strategy to deliver long-term value for our customers, team members, and shareholders.”

About UFP Technologies, Inc.

UFP Technologies is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. UFP is a vital link in the medical device supply chain and a valued outsourcing partner to many of the world's top medical device manufacturers. The Company’s single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants.